{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-061439","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.316592+00:00","generated_at":"2026-05-23T00:42:17.217150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated","bullets":["Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.","Phase 1b PIONEER trial: enrollment complete for 12mg dose cohort (n=16), 20mg cohort started.","On track to report 12mg cohort data in early Q3 2025 and 20mg cohort data by end of 2025.","R&D expenses fell to $13.4M from $19.8M due to losmapimod discontinuation and Sanofi reimbursement.","Cash runway expected to fund operations into at least 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-061439","json":"https://secwatch.observer/filing/0000950170-25-061439.json","markdown":"https://secwatch.observer/filing/0000950170-25-061439.md","text":"https://secwatch.observer/filing/0000950170-25-061439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/0000950170-25-061439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/fulc-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:42:17.217150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}